Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AnGes MG to Allocate Shares Worth 200 Million Yen to Shionogi to Develop NF-κB Decoy Oligo
May 23, 2012
- 11 Leading Foreign-Affiliated Drug Makers Report 12% Growth in Sales in 2011 Driven by New Drugs
May 23, 2012
- NDA Filed for Anti-Androgen Drug MDV3100 in the US: Astellas
May 23, 2012
- Japan Vaccine to Make All-Out Effort,“Invest All Resources” in Cervical Cancer, Rotavirus Vaccines
May 22, 2012
- Sandoz to Copromote Somatropin with Nipro Pharma
May 22, 2012
- Towa to Review Existing Products for Improved Competitiveness, Starting with 70 APIs
May 22, 2012
- Chugai to Make CNS Its Strategic Field; 3 Compounds in Pipeline: President Kosaka
May 21, 2012
- Operating Profits Up 4.2%, Business Expansion Slows Down in FY2011: Major Generics Manufacturers
May 21, 2012
- Hisamitsu Files for Transdermal Oxybutynin for Overactive Bladder
May 21, 2012
- The Growing Presence of Foreign-Affiliates (3)
May 21, 2012
- “Confident in Usefulness” of Alogliptin: President Hasegawa of Takeda
May 18, 2012
- Ono to Conduct Joint Research with German Pharmaceutical Company Using Affilin Technology
May 18, 2012
- Ishibashi to Become SSP President, Torii to Be Withdrawn from Presidency
May 18, 2012
- Morishita Jintan, AnGes MG Jointly Research and Develop Oral Vaccine
May 18, 2012
- Pfizer Resubmit NDA for Fesoterodine Fumarate in March
May 18, 2012
- Eisai Sets Domestic Sales Forecast for Aricept at 90 Billion Yen on Impact of Generics
May 17, 2012
- Double-Digit Drop in Sales, Profits Reported Due to Patent Expiration of Aricept: Eisai
May 17, 2012
- Nichi-Iko, sanofi-aventis to Copromote Lipitor Generic Aiming at Cumulative Sales of 10 Billion Yen over 5 Years
May 17, 2012
- Sawai Targets Sales of 100 Billion Yen in FY2014, Gives Up Biosimilars Development: New Midterm Plan
May 17, 2012
- FY2011 Settlement of Accounts: Second-Tier Drug Makers Struggled, Domestic-Focused Mid-Sized Makers Posted Growth
May 17, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…